Exelixis takes Cipla to court over generic cancer drug

Cipla claims Cabometyx patents are invalid | Exelixis wants generic blocked until at least 2030.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Cipla loses fightback over diarrhoea antibiotic

25 April 2023 Judge rejects notion that tribunal acted unfairly in royalties dispute with Salix | Indian firm wanted payments on sales of antibiotic | Appeal brought under act with ‘high hurdle to surmount’.

Big Pharma

BMS sues AstraZeneca for infringing cancer treatment drug

26 January 2023 US pharma giant says competitor’s drug Imjudo violates two patents | BMS’ blockbuster was first to use checkpoint inhibitors, says complaint.

Big Pharma

EU blocks $7.1bn takeover of cancer detection company

8 September 2022 Illumina bid would have “stifled innovation” | EU said Illumina was the "unrivalled supplier” of next-generation sequencing systems for genetic and genomic analysis.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Exelixis takes Cipla to court over generic cancer drug

More on this story

Editor's picks

Editor's picks

More features